ASIT biotech is a clinical stage (Phase 3) biopharmaceutical company publicly listed on EURONEXT (Brussels & Paris).
ASIT biotech’s mission is to lead an evolution in allergy therapeutics by creating a new generation of highly effective and efficient immunotherapy options for respiratory and food allergies. Our goal is to generate breakthrough treatments that deliver rapid, recognizable improvement in the life of allergy patients, within weeks rather than months or years following treatment initiation.
- ASIT biotech gp-ASIT+TM Phase III trial in grass pollen allergy did not meet the primary endpoint Monday, 25 November 2019
- Declaration of dissociation of a member of the Board of Directors at the General Assembly Friday, 15 November 2019
- ASIT biotech mode of action study of gp-ASIT+™ for grass pollen allergy published in The Journal of Allergy and Clinical Immunology (JACI) Thursday, 17 October 2019 All ASIT news
- JP Morgan, San Francisco : January 13th 2020 - 16 January 2020